Once-yearly zoledronic acid in older men compared with women with recent hip fracture. (Q53141719)

11 May 2018

title

Once-yearly zoledronic acid in older men compared with women with recent hip fracture. (English)

1 reference

11 May 2018

1 reference

2

1 reference

11 May 2018

Frank Claessens

11

1 reference

11 May 2018

An Sermon

An Sermon

12

0 references

Jean-Marc Kaufman

8

Jean-Marc Kaufman

1 reference

11 May 2018

Jay Magaziner

3

Jay Magaziner

1 reference

11 May 2018

René Rizzoli

9

Rene Rizzoli

1 reference

11 May 2018

author name string

Steven Boonen

1

1 reference

11 May 2018

Cathleen S Colón-Emeric

4

1 reference

11 May 2018

Jonathan D Adachi

5

1 reference

11 May 2018

Christina Bucci-Rechtweg

6

1 reference

11 May 2018

Patrick Haentjens

7

1 reference

11 May 2018

Dirk Vanderschueren

10

1 reference

11 May 2018

Richard Witvrouw

13

1 reference

11 May 2018

Koen Milisen

14

1 reference

11 May 2018

Guoqin Su

15

1 reference

11 May 2018

Kenneth W Lyles

16

1 reference

11 May 2018

HORIZON Recurrent Fracture Trial

17

1 reference

11 May 2018

language of work or name

English

0 references

publication date

21 October 2011

1 reference

11 May 2018

Journal of the American Geriatrics Society

published in

1 reference

11 May 2018

volume

59

1 reference

11 May 2018

issue

11

1 reference

11 May 2018

page(s)

2084-2090

1 reference

11 May 2018

Mortality after all major types of osteoporotic fracture in men and women: an observational study.

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1532-5415.2011.03666.X

Mortality, morbidity, and assessment of fracture risk in male osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1532-5415.2011.03666.X

Has mortality after a hip fracture increased?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1532-5415.2011.03666.X

Hip fractures in the elderly: a world-wide projection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1532-5415.2011.03666.X

Survival and potential years of life lost after hip fracture in men and age-matched women

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1532-5415.2011.03666.X

Mortality risk associated with low-trauma osteoporotic fracture and subsequent fracture in men and women.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1532-5415.2011.03666.X

The risk of subsequent fractures in community-dwelling men and male veterans with hip fracture

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1532-5415.2011.03666.X

Osteoporosis is markedly underdiagnosed: a nationwide study from Denmark

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1532-5415.2011.03666.X

Bone mineral density measurement and treatment for osteoporosis in older individuals with fractures: a gap in evidence-based practice guideline implementation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1532-5415.2011.03666.X

Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1532-5415.2011.03666.X

Zoledronic acid and clinical fractures and mortality after hip fracture

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1532-5415.2011.03666.X

Universal standardization of bone density measurements: a method with optimal properties for calibration among several instruments.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1532-5415.2011.03666.X

Prediction of creatinine clearance from serum creatinine

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1532-5415.2011.03666.X

Potential mediators of the mortality reduction with zoledronic acid after hip fracture

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1532-5415.2011.03666.X

Efficacy and safety of a once-yearly i.v. Infusion of zoledronic acid 5 mg versus a once-weekly 70-mg oral alendronate in the treatment of male osteoporosis: a randomized, multicenter, double-blind, active-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1532-5415.2011.03666.X

Once-weekly risedronate in men with osteoporosis: results of a 2-year, placebo-controlled, double-blind, multicenter study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1532-5415.2011.03666.X

High-trauma fractures and low bone mineral density in older women and men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1532-5415.2011.03666.X

Excess mortality in men compared with women following a hip fracture. National analysis of comedications, comorbidity and survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1532-5415.2011.03666.X

Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1532-5415.2011.03666.X

Anti-fracture efficacy of risedronic acid in men: A meta-analysis of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1532-5415.2011.03666.X

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1532-5415.2011.03666.X

Alendronate for the Treatment of Osteoporosis in Men

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1532-5415.2011.03666.X

10.1111/J.1532-5415.2011.03666.X

21 January 2018

Identifiers

DOI

1 reference

11 May 2018

PubMed ID

22091563

1 reference

11 May 2018